E. coli Nissle (EcN) is a non-pathogenic probiotic bacterium of the Enterobacteriaceae family that has been used for over a century to promote general gut health. Despite the history of safe usage of EcN, concerns have been raised regarding the presence of the pks gene cluster, encoding the genotoxin colibactin, due to its association with colorectal cancer. Here, we sought to determine the
Escherichia coli Nissle 1917 (EcN) is one of the probiotics that has drawn more attention from researchers in recent days as it extends many host beneficial effects. EcN is being used as a treatment regimen especially for gastrointestinal disorders for more than 100 years. Apart from its clinical applications in its original form, EcN is being genetically engineered to meet the therapeutic
Escherichia coli Nissle 1917 is a probiotic strain used in the treatment of intestinal immune diseases, including ulcerative colitis. The aim of the present study was to test if this probiotic bacterium can also show systemic immunomodulatory properties after oral administration.
This study systematically expanded the EcN-based toolbox, enabling EcN as a powerful platform for more applications and developing EcN native integrase-mediated genetic engineering capabilities and establishing an in vitro cell-free protein synthesis system. Escherichia coli Nissle 1917 (EcN) is a probiotic microbe that has the potential to be developed as a promising chassis for synthetic
The probiotic Escherichia coli strain Nissle 1917 (DSM 6601, Mutaflor), generally considered beneficial and safe, has been used for a century to treat various intestinal diseases. However, Nissle 1917 hosts in its genome the pks pathogenicity island that codes for the biosynthesis of the genotoxin colibactin.
An engineered probiotic designed to treat a metabolic disease enters clinical trials. E. coli Nissle 1917 has been tested in animal experiments for the treatment of inflammatory bowel disease
. 289 379 254 192 50 221 115 100 365
e coli nissle 1917 probiotic
